![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 36, 25455-25460, September 3, 1999
§,
,
, and
From the Cancer Research Campaign, The oligodendrocyte-type-2 astrocyte progenitor
cells (precursors of oligodendrocytes and type-2 astrocytes) are an
excellent system in which to study differentiation as they can be
manipulated in vitro. Maintenance of oligodendrocyte-type-2
astrocyte progenitor cells requires basic fibroblast growth factor, a
growth factor whose action normally depends on a heparan sulfate
coreceptor. Biochemical analysis revealed a most surprising result:
that the oligodendrocyte-type-2 astrocyte progenitors did not
synthesize heparan sulfate, the near ubiquitous N-sulfated
cell surface polysaccharide, but the chemically related heparin in a
form that was almost completely N- and
O-sulfated. The heparin was detected in the pericellular fraction of the cells and the culture medium. In contrast the differentiated glial subpopulations (oligodendrocytes and type-2 astrocytes) synthesized typical heparan sulfate but with distinctive fine structural features for each cell type. Thus heparin is a unique
differentiation marker in the glial lineage. Previously heparin has
been found only in a subset of mature mast cells called the connective
tissue mast cells. Its presence within the developing nervous system on
a precise population of progenitors may confer specific and essential
recognition properties on those cells in relation to binding soluble
growth and/or differentiation factors and the extracellular matrix.
In the developing rat optic nerve, bipotential glial progenitor
cells (O-2A1 progenitors)
give rise to both oligodendrocytes, which myelinate central nervous
system axons, and type-2 astrocytes, which have been proposed to
contact the axons between adjacent myelinated regions at nodes of
Ranvier (1). Small numbers of O-2A progenitors are found in the nerve
as early as embryonic day 15 (2). They continue to proliferate for
several weeks (3, 4) and differentiate in the early postnatal period
oligodendrocytes appearing before the type-2 astrocytes (5).
The O-2A progenitors represent one of the few cell types in which most
aspects of differentiation and proliferation can be manipulated in a
controlled in vitro environment. O-2A progenitors grown in
chemically defined medium in the absence of mitogen differentiate rapidly into oligodendrocytes without additional signals (6-8). If,
however, they are exposed to appropriate inducing factors like fetal
calf serum or bone morphogenic protein-2, the cells differentiate into
astrocytes (6, 9-11). Differentiation can be inhibited and O-2A
progenitor proliferation maintained by basic fibroblast growth factor
(bFGF) used either alone or in combination with PDGFA (12).
It is now well established that many growth factors and cytokines act
on target cells via a dual receptor system in which one relatively low
affinity receptor facilitates transfer to a higher affinity species
essential for cell signaling. In the case of bFGF, and other members of
the fibroblast growth factor family, the low affinity receptor is
heparan sulfate (HS) (13-15) a near ubiquitous sulfated polysaccharide
present on the cell surfaces and in the extracellular matrix as a
component of proteoglycans. A number of growth factors such as vascular
endothelial growth factor, hepatocyte growth factor, and heparin
binding growth-associated molecule (16-18) are also dependent on
HSPGs, whereas the effectiveness of others is enhanced by their
interaction with HS possibly due to a resultant increase in their
pericellular concentration. The long splice variant of PDGFA falls into
the latter category (19, 20).
Specific HS species are required to bind to these growth factors (17,
21-24). Permutations in HS structure arise from non-random but
variable O-sulfation of saccharides within
N-sulfated sections (sulfated domains) of the sugar chain
and their immediate flanking sequences. These hypervariable sulfated
regions are separated by extended sequences of N-acetylated
saccharides of low or zero sulfation (reviewed in Ref. 25). This
pattern distinguishes HS from the chemically related heparin, which is
essentially highly sulfated along its entire length and in contrast to
the ubiquitously distributed HS has so far been found only in a
subgroup of mast cells, called the connective tissue mast cells
(26).
Studies from a number of groups have shown that the patterns of
expression of HSPG core proteins and the structure of HS chains are
developmentally regulated and tightly controlled at the cellular level
(27, 28). Such changes modify cell responses to extrinsic growth and
differentiation factors and may provide guidance cues for axonal
pathfinding in the nervous system (29). In the following investigation,
the primary O-2A cells were utilized to study changes in HS composition
during differentiation of the bipotential progenitor cells into the two
functionally and morphologically distinct glial cell lineages. A
remarkable switch from heparin expression in the O-2A progenitors to
distinctive HS species in the oligodendrocytes and astrocytes was observed.
Materials--
PDGFA and bFGF for cell culture were gifts from
C. George-Nascimento and L. Coussens (Chiron Corp., Emeryville, CA),
recombinant human insulin growth factor-1 a gift from Genentech,
ciliary neurotrophic factor from Frank Collins (Synergen) and
recombinant human leukemia inhibitory factor from John Heath.
Recombinant bFGF used in the affinity experiments was given by David
Fernig (Liverpool, United Kingdom (UK)). Poly-L-lysine
(Mr 175,000), bovine pancreatic insulin, human
transferrin, progesterone, putrescine, L-thyroxine,
selenium, soybean trypsin inhibitor, and keratanase
(endo-
D-[6-3H]Glucosamine hydrochloride (20-45
Ci/mol) was obtained from NEN Life Science Products (Stevenage, UK).
Heparinase I (EC 4.2.2.7) and chondroitinase ABC (EC 4.2.2.4) were from Seikagaku Kogyo Co. (Tokyo, Japan). Heparinase II (no EC number assigned) and heparinase III (EC 4.2.2.8) were obtained from Grampian
Enzymes (Orkney Island, UK). Bio-Gel P10 and Affi-Gel 10 were purchased
from Bio-Rad (Hemel Hampstead, UK), Sepharose CL-6B and DEAE-Sephacel
from Amersham Pharmacia Biotech (St Albans, UK), and ProPac PA1
analytical columns from Dionex (Camberley, Surrey, UK).
Trizol, Superscript II, oligo(dT) primers, and Elongase polymerase were
from Life Technologies, Inc. The Advantage PCR pure kit was from
CLONTECH (Palo Alto, CA).
Purification of O-2A Progenitor Cells--
O-2A progenitor cells
were isolated from the corpus callosum from 7-day-old rats in order to
obtain the number of cells for the biochemical assays. The procedure
used was as described previously for the isolation of progenitors from
the optic nerve (6, 7). Progenitor cells were purified using a specific
antibody capture assay adapted to the O-2A lineage, which reproducibly
yields cell populations that are 95-100% pure (31). The O-2A
progenitor cells were then either maintained as progenitors in the
presence of 10 ng/ml bFGF and 10 ng/ml PDGFA (12). Differentiation to oligodendrocytes was achieved by culture in the presence of PDGFA alone
(32) and to type-2 astrocytes by addition of 10% fetal calf serum (6).
Cell populations that were generated by in vitro
differentiation were harvested at a time point where the differentiation process is complete to ensure 99-100% pure homogenous populations (7 days for oligodendrocytes and 4 days for astrocytes). This purity of the cultures was confirmed by staining control dishes
with either anti-GalC (a marker for oligodendrocytes) or anti-GFAP,
which is expressed on astrocytes.
Radiolabeling and Preparation of Glycosaminoglycans--
HS and
other glycosaminoglycans (GAGs) were biosynthetically labeled by
incubating the cultures with 10 µCi/ml [3H]glucosamine
for 48 h, to enable tracing of the material in the subsequent
experiments by scintillation counting. 3H-GAGs were
analyzed from the medium, trypsin-released (pericellular), and
intracellular fractions. The medium was removed from the cells, and
after washing in PBS the cells were treated with 3 ml of 50 µg/ml
trypsin in PBS plus 2 mM EGTA per flask for 10 min at
37 °C. Soybean trypsin inhibitor (250 µg/ml) was added, the cell suspension was pelleted in a bench-top centrifuge (1,000 rpm for 10 min), and the supernatant (i.e. pericellular fraction) was removed. The cell pellet was digested with 0.5 mg/ml Pronase in 5 ml of
PBS for approximately 16 h at 37 °C, centrifuged for 10 min at
5,000 rpm, and the supernatant (intracellular fraction) taken for analysis.
Each fraction was initially purified by ion-exchange chromatography on
a DEAE-Sephacel column (1 cm × 5 cm) equilibrated in PBS. The
GAGs were eluted with a gradient of 0.15-1.5 M NaCl in 20 mM sodium phosphate buffer, pH 7.3, at 10 ml/h. Fractions
containing radiolabeled GAGs were pooled, desalted by G50 gel
filtration chromatography (1 cm × 35 cm column) in 0.1 M NH4HCO3 and lyophilized.
Identification and Digestion of GAGs--
The different GAG
types were identified and separated from the heparin/HS using specific
degradation enzymes. Briefly HA was detected by treatment with 1 mg/ml
bovine testicular hyaluronidase in 0.1 M NaAc, 0.15 M NaCl, pH 5.0, for approximately 16 h at 37 °C.
Similarly, CS/DS was identified by their sensitivity to chondroitinase
ABC (32) and keratan sulfate by digestion with 1 unit/ml keratanase in
0.2 M NaAc, pH 7.4, for 16 h at 37 °C. The extent
of degradation was determined by Sephadex G50 gel filtration chromatography. HS and heparin were detected by their sensitivity to
low pH nitrous acid (33).
HS chains were released from proteoglycan core proteins by alkali
borohydride treatment and the molecular size distribution determined by
CL6B gel chromatography (34).
Enzymatic Degradation of Heparin and HS and Disaccharide
Analysis--
Heparinase III enzyme digestion was carried out as
described by Stringer and Gallagher (34). Complete depolymerization of the HS chains was carried out by initially digesting with two additions
of 20 mIU/ml heparinase I in 0.1 mM calcium acetate, 1 mg/ml bovine serum albumin, pH 7.0, over at least 18 h and
subsequently digesting with two additions of 20 mIU/ml amounts of both
heparinase II and III. The extent of breakdown was determined by
Bio-Gel P10 chromatography.
The disaccharides produced by combined heparinase digestion were
repeatedly lyophilized to remove NH4HCO3 and
separated by strong anion exchange chromatography on a ProPac column
linked to an Anachem HPLC system, equilibrated with double-distilled acidified water, pH 3.0. After sample injection in 2 ml of acidified water, the column was washed with 2 ml of acidified water, followed by
elution in a two-step gradient of 0-1 M NaCl, pH 3.0, over 45 ml, then 1-2 M NaCl, pH 3.0, over 3 ml. Disaccharides
were identified by comparison with elution positions of eight known standards.
Affinity Chromatography--
To prepare a bFGF affinity gel
column, 200 µg of recombinant bFGF was mixed with 200 µg of heparin
in 100 µl of coupling buffer (0.1 M HEPES, 80 mM NaCl, pH 7.0) and incubated for 20 min at room
temperature. The bFGF was then bound to Affi-Gel 10, and the column
prepared as described for a hepatocyte growth factor affinity column by
Lyon et al. (17), alongside a control column where the bFGF
was omitted.
Affinity experiments were performed by application of radiolabeled HS
or CS/DS samples in a 20 mM sodium phosphate buffer containing 0.15 M NaCl and pH 7.3. The sample of HS was
recirculated through the column at least five times at room temperature
to maximize its opportunity to bind to bFGF. The sample was then eluted
by a stepwise NaCl gradient from 0.15 to 2.0 M NaCl in 20 mM sodium phosphate. Fractions (0.5 ml) were collected and monitored for radioactivity.
Detection of Gene Expression by RT-PCR--
Total RNA was
isolated from cells or whole tissues by a modification of the guanidine
isothiocyanate-phenol-chloroform extraction method using Trizol
reagent. cDNA was synthesized from 1-5 µg of total RNA in a
20-µl reaction using Superscript II, a modified Moloney murine
leukemia virus reverse transcriptase, and oligo(dT)12-18 primers according to the Life Technologies, Inc. protocol.
Aliquots of cDNA, equivalent to 1/20 of the above reaction, were
used in a 50-µl PCR reaction. PCR amplification was performed using
Elongase polymerase under conditions recommended by the manufacturer.
The 5' and 3' primers, all written 5' to 3', are glypican,
GACATACACATTCAGACCC, CTAAGAAACCCACAGACC (product 393 bp);
syndecan 1, GACAACTTCTCTGGCTCAGG, CTTCGTCCTTCTTCTTCATCC (735 bp);
syndecan 2, GACTATTCTTCTTCTGCCTCTGGC, GGTTTGCGTTCTCCAAGGTC (409 bp);
syndecan 3, CCATGCGGTTCATTCCTGAC, CGATGGCATTGTCGTGGAG (800 bp); and
syndecan 4, GTCATAGACCCCCAGGACC, CCCTTTTGGGAATGACCTC (267 bp).
Reactions were run for 35 cycles. A 10-min incubation at 72 °C
added at the end ensured complete extension. The PCR products were
purified using the Advantage PCR-Pure kit and their authenticity
checked by sequence analysis and restriction enzyme digestion.
Proteoglycan Expression in O-2A Progenitors and Differentiated
Cells--
RNA isolated from primary cultures of O-2A progenitor cells
and from cultures allowed to differentiate into oligodendrocytes and
astrocytes was analyzed for expression of the most common HSPG types by
RT-PCR. Expression of syndecans 1, 2, 3, and 4 and glypican was found
in the progenitors, oligodendrocytes, and astrocytes. There was no
indication of serglycin expression by RT-PCR using two different sets
of mouse primers, as unlike the other proteoglycans mentioned there was
no rat serglycin DNA sequence information available. RT-PCR analysis
also showed that all of the three cell types expressed the bFGF
receptor, FGFR2 type IIIc, with FGFR1 type IIIc additionally expressed
by the oligodendrocytes (data not shown).
GAG Composition of the O-2A Progenitors, Oligodendrocytes, and
Astrocytes--
Metabolically radiolabeled GAG saccharide chains were
isolated and analyzed from primary cultures of O-2A progenitor cells and the differentiated cell types. In all cultures the majority of GAGs
were found in the culture medium and CS/DS was consistently the major
species (Fig. 1). There was very little
intracellular material. HS/heparin, identified on the basis of nitrous
acid susceptibility, was present in all cell types with a general
tendency for the heparin/HS:CS/DS ratio to increase in the pericellular fraction. There was a dramatic depletion in the level of heparin/HS in
the oligodendrocytes compared with the O-2A progenitors with an average
decrease of 80% ± 20% in the pericellular fraction, coinciding with
a drop in CS/DS levels. In the astrocytes there was always an increase
of at least 2-fold in the level of CS in the medium compared with the
progenitor cells. Small quantities of HA were present in all of the
cultures, and a trace of keratan sulfate was found in the pericellular
fraction of the progenitors in one of three preparations of the
cells.
Analysis of Heparin/HS Structure--
The heparin/HS was further
purified, and the size distribution for each cell type was determined
by gel filtration chromatography on Sepharose CL6B (Fig.
2). The peak maxima for the progenitors, oligodendrocytes, and astrocytes corresponded to
Kav values of 0.52, 0.49, and 0.42 respectively
(Fig. 2) equivalent to mean molecular masses of 20 ± 1.4, 25 ± 3.8, and 31 ± 2.4 kDa by reference to the published
calibration of Wasteson (35). No differences were observed in the size
range of material isolated from the medium and pericellular fractions
for each cell type. The progenitor and oligodendrocyte heparin/HS
showed broad size distributions typical of previously isolated HS
species, while the astrocyte polysaccharide had a noticeably tighter
distribution.
Heparin/HS from the medium and pericellular compartments was
depolymerized by nitrous acid degradation and heparinase III enzyme to
compare their structures. The resultant fragments were separated on a
Bio-Gel P10 column. In all cases the polysaccharide from the medium and
pericellular compartments within each cell type showed essentially the
same characteristics.
Treatment with low pH nitrous acid, which cleaves at
GlcNSO3 residues, gave striking results for the progenitor
polysaccharide, where 94% of the material was broken down to
disaccharides, indicating that the material has an N-sulfate
content comparable to that of heparin (Fig.
3A). In contrast both the
oligodendrocytes and astrocytes showed a typical HS breakdown pattern
(Fig. 3, B and C) with a range of different sized
nitrous acid-resistant fragments similar to HS extracted from a variety
of other cell types (e.g. Ref. 36). Overall the degrees of
N-sulfation of the progenitors, oligodendrocytes and
astrocytes were 95%, 42%, and 39%, respectively. It was noticeable
that the nitrous acid-resistant fragments from the astrocytes HS
contained a greater proportion of hexasaccharide and longer fragments
than in the oligodendrocyte HS.
Heparinase III is proposed to cleave the linkage
GlcNAc/GlcNSO3(± 6S) Disaccharide Composition--
Disaccharides were prepared from the
three cell types by combined heparinase digestion and separation on
Bio-Gel P10, followed by strong anion-exchange HPLC. Analysis of the
disaccharide composition (Fig.
4A) confirms the distinctive
heparin nature of the progenitor HS, which contained 73% trisulfated
disaccharides (UA(2S)-GlcNSO3(6S)) and no
N-acetylated disaccharides (Table
I). The contrast to the disaccharide
elution profiles of the differentiated cell types is immediately
apparent (Fig. 4, B and C), where a range of all of the eight disaccharide types commonly seen in HS were present (Table
I). In both cases there was over 30% non-sulfated disaccharides and
less than 15% were trisulfated. The disaccharide composition of the
astrocytes was very similar to that found in human skin fibroblast HS
(36). The oligodendrocytes HS disaccharide composition was distinct
from the astrocytes, with a significantly higher level of the
trisulfated disaccharide.
Affinity of the HS for bFGF--
As bFGF is known to be a key
growth factor for regulating the proliferation and differentiation of
the O-2A cell type (12), the relative affinities of the different glial
HS types for a bFGF Affi-Gel column were compared. In all cases the
majority of HS eluted between 0.15 and 1 M NaCl, with a
small amount of HS binding at high affinity up to at least 1.6 M NaCl (Fig. 5). A control
column did not exhibit any binding of HS above 0.15 M NaCl
(data not shown). The progenitor heparin showed stronger binding to the
bFGF Affi-Gel than the oligodendrocyte HS with a greater proportion of
the material eluting at 0.8 M NaCl and above, while the
astrocyte HS elution profile was more analogous to the progenitors. The
bFGF affinity of the astrocyte HS was not significantly different from
mouse fibroblast HS (Fig. 5B) consistent with their
similarity in composition (Fig. 3; Ref. 34). CS/DS from the progenitors
and oligodendrocytes showed much weaker binding to the bFGF Affi-Gel,
the majority of material eluting between 0.15 M and 0.4 M NaCl with no binding seen above 0.6 M NaCl
(data not shown).
The results in this paper clearly indicate that O-2A progenitor
cells produce heparin (Figs. 3 and 4). Heparin has only previously been
found in connective tissue mast cells. This finding was both interesting and unexpected, and on differentiation to either type-2 astrocytes or oligodendrocytes there was a switch to HS expression. Furthermore neuroepithelial cells, which are thought to be
developmental precursors to the O-2A progenitor cells (38-40), produce
HS rather than heparin (28).
During heparin/HS biosynthesis (for reviews, see Refs. 25, 41, and 42),
the N-deacetylase/N-sulfotransferase (NDST) enzymes commit the polymeric precursor heparan, composed of repeat sequences of GlcA In contrast to the connective tissue mast cells, where heparin is
stored in intracellular secretory granules attached to the protease-resistant core protein serglycin (46), the O-2A heparin was
only found in the medium and pericellular (i.e.
trypsin-releasable) fractions (Fig. 1). Furthermore, RT-PCR studies did
not detect any expression of the serglycin proteoglycan (data not
shown). RT-PCR studies indicated that all four syndecans and glypican HSPGs are expressed in the O-2A progenitors, oligodendrocytes, and
astrocytes but it cannot be certain that these O-2A proteoglycans bear
the heparin chains.
A novel HSPG that appears to be important in central nervous system
development has been found in the primitive neuroepithelial cells (47),
which are precursors to the O-2A cells. Analysis of the HS chains from
embryonic day 10 (E10) and day 12 (E12) neuroepithelial precursor cells
showed that changes in structure in the form of an increase in chain
length and 6-O-sulfation in the more committed E12 cells
(28) corresponded to a switch in growth factor response of the cells
from bFGF in E10 to aFGF in E12. bFGF is also known to be important for
the self-renewal property of the O-2A progenitors (12). In this paper
we found that the switch from heparin in the O-2A progenitors to the
much lower sulfated HS in the oligodendrocytes corresponded to a
significant decrease in the apparent bFGF affinity of the
polysaccharide chains (Fig. 5). This might be expected, as both
N-sulfation and 2-O-sulfation of the HS chains
have been found to be important for bFGF binding (21-23), while
6-O-sulfation appears to be critical for biological activation (48-50). However, the astrocyte HS bound bFGF as
efficiently as the more highly sulfated progenitor heparin (Fig. 5),
possibly as a result of the prevalence of long sulfated domains
(dodecasaccharides and larger) within the astrocyte HS (Fig.
3F).
Although oligodendrocytes are postmitotic (51), they still respond to
bFGF by down-regulation of myelin-specific markers, re-entrance into
the cell cycle without mitosis, and increase in the length of cellular
processes (52). The present results indicate that this response to bFGF
may be less reliant on the HS coreceptor, which is at low levels (Fig.
1) and has low bFGF affinity (Fig. 5) than other cell systems (13-15)
and could possibly be mediated by the signaling receptor FGFR2 type
IIIc, which is not found in the the progenitors or astrocytes.
The long splice variant of the other key growth factor in this system,
PDGFA (12), has recently been discovered to bind to highly sulfated
heparin like oligosaccharides, enriched in the trisulfated
disaccharides (24), which form 74% of the O-2A progenitor heparin
(Table I). PDGFA is critical for the timing of the O-2A progenitor
differentation into oligodendrocytes and astrocytes (31, 51), and
heparin may be essential in regulating the PDGFA response.
The specific temporal expression of heparin, in the O-2A progenitors,
during central nervous system development suggests that heparin must
have a function critical to this lineage or to the adjacent neurons. It
would be interesting to discover whether heparin is also produced by
the subset of glioblastoma multiforme tumors believed to be derived
from the small population of adult O-2A progenitor cells (53), as it
might enhance the activity of the myriad of autocrine growth factors
mitogenic to glioblastomas (e.g. Refs. 54-57). Similarly,
during injury of the central nervous system where reactive astrocytes
are thought to revert to a more primitive state (for reviews, see Refs.
58 and 59), reappearance of heparin expression could possibly aid their
rapid response. Further study of the heparin produced by O-2A
progenitors could give important insights into the control of heparin
and HS biosynthesis and their role in both development and disease states.
We gratefully acknowledge Naomi Chadderton
and Abdul Patel (Paterson Institute of Cancer Research, Manchester,
UK), and Samuel Bernard (University of Utah, Salt Lake City, UT) for
technical assistance. We also acknowledge Mark Noble (University of
Utah, Salt Lake City, UT) for advice and support.
*
This work was supported by the Cancer Research Campaign and
the Huntsman Cancer Institute.The costs of publication of this article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom all correspondence should be addressed. Tel.:
44-161-446-3035; Fax: 44-161-446-3109; E-mail:
sstringer@picr.man.ac.uk.
The abbreviations used are:
O-2A, oligodendrocyte-type-2 astrocyte;
2S, 2-OSO3;
6S, 6-OSO3;
bFGF, basic fibroblast growth factor;
bp, base pair(s);
CS, chondroitin sulfate;
DS, dermatan sulfate;
E, embryonic
day;
FGFR, fibroblast growth factor receptor;
GlcA,
Drug Development
and Imaging Section,
Department of Neurobiology and Anatomy, University of Utah
Medical School, Salt Lake City, Utah 84132
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-galactosidase, EC 3.2.1.103) were obtained from Sigma (Poole,
UK). Bovine serum albumin was from Miles Laboratories Inc.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (11K):
[in a new window]
Fig. 1.
GAG composition of glial progenitors and
differentiated cells. 3H-Radiolabeled GAG chains were
extracted from the medium (M), pericellular (P),
and intracellular (I) fractions of primary O-2A progenitors,
and from the oligodendrocytes and astrocytes into which a proportion of
them had been differentiated in culture. HA (open bar) was separated from the other GAGs by anion exchange
chromatography and its presence confirmed by testicular hyaluronidase
digestion. CS/DS (solid bar) were removed from
the remaining sulfated GAGs and their levels determined by breakdown
with specific enzymes. A tiny amount of keratan sulfate found in the
pericellular fraction of one preparation of progenitors was similarly
removed by specific enzyme breakdown. The remaining material was
confirmed to be HS/heparin (striped bar) by
nitrous acid treatment. The histogram depicts mean values from three
preparations of cells. The standard errors for each data category are
as follows: O-2A progenitors, HA, M 0.003, P 0.008, I 0; HS, M 0.069, P
0.011, I 0; CS, M 0.028, P 0.023, I 0. Oligodendrocytes, HA, M 0.005, P
0.005, I 0.005; HS, M 0.026, P 0.010, I 0; CS, M 0.16, P 0.020, I 0. Astrocytes, HA, M 0.012, P 0.004, I 0.009; HS, M 0.035, P 0.002, I 0;
CS, M 0.005, P 0.003, I 0.

View larger version (19K):
[in a new window]
Fig. 2.
CL6B-Sepharose gel filtration of HS/heparin
chains. The size distribution of the 3H-radiolabeled
HS/heparin purified from O-2A progenitor (solid line), oligodendrocyte (dotted line),
and astrocyte (dashed line) extracts were
compared by CL6B gel filtration chromatography. The position of the
column void volume (VO) and total volume (VT) is
indicated. The CL6B-Sepharose gel filtration analysis has been carried
out several times on the three preparations of the different cell types
in Fig. 1.

View larger version (37K):
[in a new window]
Fig. 3.
Depolymerization of HS/heparin by nitrous
acid treatment or heparinase III enzyme digestion.
3H-Radiolabeled heparin/HS from the O-2A progenitors
(A and D), oligodendrocytes (B and
E), and astrocytes (C and F) were
depolymerized by low pH nitrous acid treatment (A-C) or
heparinase III enzyme digestion (D-F) and the resultant
fragments separated by Bio-Gel P10 gel filtration. The degree of
polymerization of the oligosaccharides within each peak and the
position of the column void volume (Vo) are indicated. Each
of the depolymerization treatments illustrated has been carried out at
least three times with heparin/HS from at least two preparations of
cells, and the results were consistent.
1,4GlcA/IdoA (36, 37), with a
preference for the GlcA-bearing disaccharides. It thereby attacks
mainly in the non-sulfated regions releasing N-sulfated
fragments enriched in IdoA(2S). The low level of heparinase III
cleavage of the progenitor polysaccharide, about 5% susceptible
linkages (Fig. 3D), with most of the material eluting in the
column void volume (Fig. 3D) indicates an IdoA(2S)-rich, polysaccharide species (i.e. heparin). The switch to HS
expression was clearly seen in the two differentiated cell types, the
oligodendrocytes and the astrocytes, which had 49% and 54% heparinase
III-susceptible linkages, respectively, with a range of different sized
sulfated domains being identifiable in the elution profiles (Fig. 3,
E and F). Again the profile of the astrocytes was
distinct from the oligodendrocytes, with a greater proportion of the
longer sulfated domains of decasaccharides and above.

View larger version (23K):
[in a new window]
Fig. 4.
Analysis of the disaccharide composition of
O-2A progenitor, oligodendrocyte, and astrocyte HS/heparin.
Disaccharides that were prepared by exhaustive heparinase enzyme
digestion of the [3H]HS/heparin from the O-2A progenitors
(A), oligodendrocytes (B), and astrocytes
(C) were separated on a ProPac PA1 strong anion exchange
HPLC analytical column (4 × 250 mm) eluted with a NaCl gradient
as described under "Experimental Procedures." The elution positions
of the sample disaccharide peaks, identified by scintillation counting
of the eluting fractions, were compared with the elution positions of
eight known disaccharide standards as follows: 1,
HexA-GlcNAc; 2,
HexA-GlcNSO3;
3,
HexA-GlcNAc(6S); 4,
HexA(2S)-GlcNAc;
5,
HexA-GlcNSO3(6S); 6,
HexA(2S)-GlcNSO3; 7,
HexA(2S)-GlcNAc(6S);
8,
HexA(2S)-GlcNSO3(6S), and the sample peaks
have been numbered accordingly. The peak depicted by the
asterisk is also considered to be standard 1,
HexA-GlcNAc, the elution position of which has been found to be
extremely sensitive to minute changes in the column environment.
Disaccharide composition of HS from the progenitors and differentiated
cells

View larger version (25K):
[in a new window]
Fig. 5.
bFGF affinity chromatography of
heparin/HS. 3H-Radiolabeled HS/heparin from O-2A
progenitors (A, solid block),
oligodendrocytes (A, striped block),
astrocytes (B, solid block), and mouse
3T3 fibroblasts (B, striped block)
were applied to a bFGF Affi-Gel column in 0.15 M NaCl.
Bound material was eluted with a stepwise gradient of NaCl, increasing
in 0.2 M steps from 0.4 M subsequent to a 0.15 M wash.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1-4GlcNAc, to heparin or HS by catalyzing the conversion of an appropriate proportion of GlcNAc residues to GlcNSO3. The simplest explanation of the present results
would be that the O-2A progenitors express the NDST isoform isolated from the heparin-synthesizing mouse mastocytoma (NDST2), which catalyzes conversion of over 80% of the GlcNAc residues to
GlcNSO3 and the differentiated cells express the rat liver
isoform (NDST1) assumed to be important for HS biosynthesis (43).
However, these enzymes were found to be widely expressed in murine and
human tissues, suggesting that the enzymes work in concert to achieve the level of N-sulfation appropriate to the cell type (43,
44). Overexpression of the mastocytoma enzyme (NDST2) in a human kidney cell line resulted in highly N-sulfated heparin in which the
other modifications, e.g. conversion of GlcA to IdoA and
polymer O-sulfation were not enhanced (45), demonstrating
that the overall structure of the polymer in any individual cell type
depends on the coordinated expression of all the modifying enzymes and
perhaps also on other regulatory proteins.
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
![]()
ABBREVIATIONS
-D-glucuronate;
GlcNAc,
-D-N-acetylglucosamine;
GlcNSO3,
-D-N-sulfoglucosamine;
GAG, glycosaminoglycan;
HA, hyaluronic acid;
HPLC, high performance liquid
chromatography;
HS, heparan sulfate;
HSPG, HS proteoglycan;
IdoA,
-L-iduronate;
NDST, N-deacetylase/N-sulfotransferase;
PBS, phosphate-buffered saline;
PCR, polymerase chain reaction;
PDGFA, platelet-derived growth factor A;
RT-PCR, reverse
transcription-polymerase chain reaction;
HexA,
4,5-unsaturated hexuronate.
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
ffrench-Constant, C.,
and Raff, M. C.
(1986)
Nature
323,
335-338[CrossRef][Medline]
[Order article via Infotrieve]
2.
Small, R. K.,
Riddle, P.,
and Noble, M.
(1987)
Nature
328,
155-157[CrossRef][Medline]
[Order article via Infotrieve]
3.
Skoff, R. P.,
Price, D. L.,
and Stocks, A.
(1976)
J. Comp. Anat.
169,
291-311
4.
Skoff, R. P.,
Price, D. L.,
and Stocks, A.
(1976)
J. Comp. Anat.
169,
313-323
5.
Miller, R. H.,
David, S.,
Patel, R.,
Abney, E. R.,
and Raff, M. C.
(1985)
Dev. Biol.
111,
35-41[CrossRef][Medline]
[Order article via Infotrieve]
6.
Raff, M. C.,
Miller, R. H.,
and Noble, M.
(1983)
Nature
303,
390-396[CrossRef][Medline]
[Order article via Infotrieve]
7.
Noble, M.,
and Murray, K.
(1984)
EMBO J.
3,
2243-2247[Medline]
[Order article via Infotrieve]
8.
Raff, M. C.,
Abney, E. R.,
and Fok-Seang, J.
(1985)
Cell
42,
61-69[CrossRef][Medline]
[Order article via Infotrieve]
9.
Hughes, S. M.,
Lillien, L. E.,
Raff, M. C.,
Rohrer, H.,
and Sendtner, M.
(1988)
Nature
335,
70-73[CrossRef][Medline]
[Order article via Infotrieve]
10.
Lillien, L. E.,
Sendtner, M.,
Rohrer, H.,
Hughes, S. M.,
and Raff, M. C.
(1988)
Neuron
1,
485-494[CrossRef][Medline]
[Order article via Infotrieve]
11.
Mabie, P. C.,
Mehler, M. F.,
Marmur, R.,
Papavasiliou, A.,
Song, Q.,
and Kessler, J. A.
(1997)
J. Neurosci.
17,
4112-4120 12.
Bogler, O.,
Wren, D.,
Barnett, S. C.,
Land, H.,
and Noble, M.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
6368-6372 13.
Yayon, A.,
Klagsbrun, M.,
Esko, J. D.,
Leder, P.,
and Ornitz, D. M.
(1991)
Cell
64,
841-848[CrossRef][Medline]
[Order article via Infotrieve]
14.
Rapraeger, A. C.,
Krufta, A.,
and Olwin, B. B.
(1991)
Science
252,
1705-1708 15.
Ornitz, D. M.,
Yayon, A.,
Flanagan, J. G.,
Svahn, C. M.,
Levi, E.,
and Leder, P.
(1992)
Mol. Cell. Biol.
12,
240-247 16.
Gitay-Goren, H.,
Soker, S.,
Vlodavsky, I.,
and Neufeld, G.
(1992)
J. Biol. Chem.
267,
6093-6098 17.
Lyon, M.,
Deakin, J. A.,
Mizuno, K.,
Nakamura, T.,
and Gallagher, J. T.
(1994)
J. Biol. Chem.
269,
11216-11223 18.
Kinnunen, T.,
Raulo, E.,
Nolo, R.,
Maccarana, M.,
Lindahl, U.,
and Rauvala, H.
(1996)
J. Biol. Chem.
271,
2243-2248 19.
Kelly, J. L.,
Sanchez, A.,
Brown, G. S.,
Chesterman, C. N.,
and Sleigh, M. J.
(1993)
J. Cell Biol.
121,
1153-1163 20.
Andersson, M.,
Ostman, A.,
Westermark, B.,
and Heldin, C.-H.
(1994)
J. Biol. Chem.
269,
926-930 21.
Turnbull, J. E.,
Fernig, D. G.,
Ke, Y.,
Wilkinson, M.,
and Gallagher, J. T.
(1992)
J. Biol. Chem.
267,
10337-10341 22.
Habuchi, H.,
Suzuki, S.,
Saito, T.,
Tamura, T.,
Harada, T.,
Yoshida, K.,
and Kimata, K.
(1992)
Biochem. J.
285,
805-813
23.
Maccarana, M.,
Casu, B.,
and Lindahl, U.
(1993)
J. Biol. Chem.
268,
23898-23905 24.
Feyzi, E.,
Lustig, F.,
Fager, G.,
Spillmann, D.,
Lindahl, U.,
and Salmivirta, M.
(1997)
J. Biol. Chem.
272,
5518-5524 25.
Stringer, S. E.,
and Gallagher, J. T.
(1997)
Int. J. Biochem. Cell Biol.
29,
709-714[CrossRef][Medline]
[Order article via Infotrieve]
26.
Linhart, R. J.,
Ampofo, S. A.,
Fareed, J.,
Hoppensteadt, D.,
Mulliken, J. B.,
and Folkman, J.
(1992)
Biochemistry
31,
12441-12445[CrossRef][Medline]
[Order article via Infotrieve]
27.
David, G.,
Bai, X. M.,
Van Der Schueren, B.,
Cassiman, J.-J.,
and Van Der Berghe, H.
(1992)
J. Cell Biol.
119,
961-975 28.
Brickman, Y. G.,
Ford, M. D.,
Gallagher, J. T.,
Nurcombe, V.,
Bartlett, P. F.,
and Turnbull, J. E.
(1998)
J. Biol. Chem.
273,
4350-4359 29.
Walz, A.,
McFarlane, S.,
Brickman, Y. G.,
Nurcombe, V.,
Bartlett, P. F.,
and Holt, C. E.
(1997)
Development
124,
2421-2430[Abstract]
30.
Deleted in proof
31.
Raff, M. C.,
Lillien, L. E.,
Richardson, W. D.,
Burne, J. F.,
and Noble, M.
(1988)
Nature
333,
562-565[CrossRef][Medline]
[Order article via Infotrieve]
32.
Turnbull, J. E.,
and Gallagher, J. T.
(1990)
Biochem. J.
265,
715-724[Medline]
[Order article via Infotrieve]
33.
Shively, J. E.,
and Conrad, H. E.
(1976)
Biochemistry
15,
3943-3950[CrossRef][Medline]
[Order article via Infotrieve]
34.
Stringer, S. E.,
and Gallagher, J. T.
(1997)
J. Biol. Chem.
272,
20508-20514 35.
Wasteson, A.
(1971)
J. Chromatogr.
59,
87-97[CrossRef][Medline]
[Order article via Infotrieve]
36.
Desai, U. R.,
Wang, H.-M.,
and Linhardt, R. J.
(1993)
Biochemistry
32,
8140-8145[CrossRef][Medline]
[Order article via Infotrieve]
37.
Yamada, S.,
Murakami, T.,
Tsuda, H.,
Yoshida, K.,
and Sugahara, K.
(1995)
J. Biol. Chem.
270,
8696-8705
38.
Rao, M. S.,
and Mayer-Proschel, M.
(1997)
Dev. Biol.
188,
48-63[CrossRef][Medline]
[Order article via Infotrieve]
39.
Mayer-Proschel, M.,
Kalyani, A.,
Mujitaba, T.,
and Rao, M. S.
(1997)
Neuron
19,
773-785[CrossRef][Medline]
[Order article via Infotrieve]
40.
Kalyani, A.,
Hobson, K.,
and Rao, M. S.
(1997)
Dev. Biol.
186,
202-223[CrossRef][Medline]
[Order article via Infotrieve]
41.
Lindahl, U.
(1989)
in
Heparin: Chemical and Biological Properties, Clinical Applications
(Lane, D. A.
, and Lindahl, U., eds)
, pp. 159-189, Edward Arnold, London
42.
Lindahl, U.,
Lidholt, K.,
Spillmann, D.,
and Kjellen, L.
(1994)
Thrombosis Res.
75,
1-32[CrossRef][Medline]
[Order article via Infotrieve]
43.
Kusche-Gullberg, M.,
Eriksson, I.,
Pikas, D. S.,
and Kjellen, L.
(1998)
J. Biol. Chem.
273,
11902-11907 44.
Aikawa, J.,
and Esko, J. D.
(1999)
J. Biol. Chem.
274,
2690-2695 45.
Cheung, W.-F.,
Eriksson, I.,
Kusche-Gullberg, M.,
Lindahl, U.,
and Kjellen, L.
(1996)
Biochemistry
35,
5250-5256[CrossRef][Medline]
[Order article via Infotrieve]
46.
Stevens, R. L.,
Avraham, S.,
Gartner, M. C.,
Bruns, G. A. P.,
Austen, K. F.,
and Weis, J. H.
(1988)
J. Biol. Chem.
263,
7287-7291 47.
Joseph, S. J.,
Ford, M. D.,
Barth, C.,
Portbury, S.,
Bartlett, P. F.,
Nurcombe, V.,
and Greferath, U.
(1996)
Development
122,
3443-3452[Abstract]
48.
Rusnati, M.,
Coltrini, D.,
Caccia, P.,
Dell'Era, P.,
Zoppetti, G.,
Oreste, P.,
Vasaina, B.,
and Presta, M.
(1994)
Biochem. Biophys. Res. Commun.
203,
450-458[CrossRef][Medline]
[Order article via Infotrieve]
49.
Guimond, S.,
Maccarana, M.,
Olwin, B. B.,
Lindahl, U.,
and Rapraeger, A. C.
(1993)
J. Biol. Chem.
268,
23906-23914 50.
Pye, D. A.,
Vives, R. R.,
Turnbull, J. E.,
Hyde, P.,
and Gallagher, J. T.
(1998)
J. Biol. Chem.
273,
22936-22942 51.
Lillien, L. E.,
and Raff, M. C.
(1990)
Neuron
5,
111-119[CrossRef][Medline]
[Order article via Infotrieve]
52.
Bansal, R.,
and Pfeiffer, S. E.
(1997)
J. Neurosci. Res.
50,
215-228[CrossRef][Medline]
[Order article via Infotrieve]
53.
Noble, M.,
and Mayer-Proschel, M.
(1997)
J. Neuro-Oncol.
35,
193-209[CrossRef][Medline]
[Order article via Infotrieve]
54.
Libermann, T. A.,
Nusbaum, H. R.,
Razon, N.,
Kris, R.,
Lax, I.,
Soreq, H.,
Whittle, N.,
Waterfield, M. D.,
Ullrich, A.,
and Schlessinger, J.
(1985)
Nature
313,
144-147[CrossRef][Medline]
[Order article via Infotrieve]
55.
Maxwell, M.,
Naber, S. P.,
Wolfe, H. J.,
Hedley-Whyte, E. T.,
Galanopoulos, T.,
Neville-Golden, J.,
and Antoniades, H. N.
(1991)
Cancer Res.
51,
1345-1351 56.
Hamel, W.,
Westphal, M.,
and Shepard, H. M.
(1992)
Int. J. Oncol.
1,
673-682
57.
Vassbotn, F. S.,
Ostman, A.,
Langeland, N.,
Holmsen, H.,
Westermark, B.,
Heldin, C.-H.,
and Nister, M.
(1994)
J. Cell. Physiol.
158,
381-389[CrossRef][Medline]
[Order article via Infotrieve]
58.
Norenberg, M. D.
(1996)
in
The Role of Glia in Neurotoxicity
(Aschner, M.
, and Kimelberg, H. K. K., eds)
, pp. 93-107, CRC Press, Boca Raton, FL
59.
Aschner, M.
(1998)
NeuroToxicol.
19,
269-282
[Medline]
[Order article via Infotrieve]
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
This article has been cited by other articles:
![]() |
K. Grobe, M. Inatani, S. R. Pallerla, J. Castagnola, Y. Yamaguchi, and J. D. Esko Cerebral hypoplasia and craniofacial defects in mice lacking heparan sulfate Ndst1 gene function Development, August 15, 2005; 132(16): 3777 - 3786. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. K. Lau, C. D. Paavola, Z. Johnson, J.-P. Gaudry, E. Geretti, F. Borlat, A. J. Kungl, A. E. Proudfoot, and T. M. Handel Identification of the Glycosaminoglycan Binding Site of the CC Chemokine, MCP-1: IMPLICATIONS FOR STRUCTURE AND FUNCTION IN VIVO J. Biol. Chem., May 21, 2004; 279(21): 22294 - 22305. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Powell, E. A. Yates, D. G. Fernig, and J. E. Turnbull Interactions of heparin/heparan sulfate with proteins: Appraisal of structural factors and experimental approaches Glycobiology, April 1, 2004; 14(4): 17R - 30R. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Stringer, B. S. Kandola, D. A. Pye, and J. T. Gallagher Heparin sequencing Glycobiology, February 1, 2003; 13(2): 97 - 107. [Abstract] [Full Text] [PDF] |
||||
![]() |
B.-M. Loo and M. Salmivirta Heparin/Heparan Sulfate Domains in Binding and Signaling of Fibroblast Growth Factor 8b J. Biol. Chem., August 30, 2002; 277(36): 32616 - 32623. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Powell, D. G. Fernig, and J. E. Turnbull Fibroblast Growth Factor Receptors 1 and 2 Interact Differently with Heparin/Heparan Sulfate. IMPLICATIONS FOR DYNAMIC ASSEMBLY OF A TERNARY SIGNALING COMPLEX J. Biol. Chem., August 2, 2002; 277(32): 28554 - 28563. [Abstract] [Full Text] [PDF] |
||||
![]() |
K Prydz and K. Dalen Synthesis and sorting of proteoglycans J. Cell Sci., January 1, 2000; 113(2): 193 - 205. [Abstract] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |